Drugs /

naratuximab emtansine

Back to Drugs List

Overview

NCI Definition [1]:
An immunoconjugate that consists of a humanized IgG1 antibody K7153A against the cell-surface antigen CD37 and covalently linked via the uncleavable, maleimide-derived thioether-based linker SMCC to the maytansinoid DM1, with potential pro-apoptotic and cytotoxic activities. Upon administration of naratuximab emtansine, the antibody moiety of IMGN529 binds to CD37 on tumor B-cells and induces an antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), thereby showing pro-apoptotic activity. In addition, after the internalization of this agent and lysosomal degradation, the DM1 moiety binds to tubulin and inhibits tubulin polymerization and microtubule assembly, resulting in a disruption of microtubule activity and cell division, and eventually causing cell death in CD37-positive B-cells. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies. Compared to reducible, cleavable linkers, the non-reducible SMCC linker shows increased stability in plasma.

Clinical Trials

View Clinical Trials for naratuximab emtansine

Naratuximab emtansine has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating naratuximab emtansine, 1 is phase 2 (0 open).

Diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma are the most common diseases being investigated in naratuximab emtansine clinical trials [2].

Drug Details

Synonyms [2]:
imgn529, anti-cd37 antibody-drug conjugate imgn529, imgn529 conjugate, anti-cd37 antibody-drug conjugate imgn529, debio 1562
NCIT ID [1]:
C100101

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.